Medgenics Inc

Medgenics to Host Business Update Conference Call

RNS Number : 1200S
Medgenics Inc
04 November 2013
 



 

 

Press Release

4 November 2013

 

 

Medgenics to Host Business Update Conference Call on Friday, November 8th at 8:30 a.m. Eastern time

 

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) ("the Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company will host an investment community conference call on Friday, November 8, 2013 beginning at 8:30 a.m. Eastern time to provide a business update and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-664-6134 (from within the U.S.) or 702-495-1913 (from outside the U.S.) or 1-809-457-877 (toll-free from Israel) and entering passcode 94707205. The call also will be broadcast live on the internet at www.streetevents.com, www.earnings.com and www.medgenics.com.

 

A replay of the conference call will be accessible two hours after its completion through November 14, 2013 by dialing (855) 859-2056 (from within the U.S.) or (404) 537-3406 (from outside the U.S.) and entering passcode 94707205. The call will also be archived for 90 days at www.streetevents.com, www.earnings.com and www.medgenics.com.

 

About Medgenics

 

Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others.  For more information, please visit www.medgenics.com

 

 

Forward-looking Statements

 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

 

 

Contacts:

 

Medgenics, Inc.

John Leaman, CFO

[email protected]

 


LHA

Anne Marie Fields,

[email protected]

@LHA_IR_PR

 

212-838-3777

Abchurch Communications

Joanne Shears / Jamie Hooper / Harriet Rae

[email protected]

 

+44 207 398 7718

 

Oriel Securities (NOMAD & Joint Broker)

Jonathan Senior / Giles Balleny

 

+44 207 710 7617 

 

SVS Securities plc (Joint Broker)

Alex Brearley

 

+44 203 700 0100

 

 

 

   

-Ends-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKQDQDBDDCDK